Close Menu

Abbott

Sales for its cardiometabolic tests dropped sharply, while sales for its flu tests soared and its consumer diagnostics sales were flat.

HTG Molecular Diagnostics has amended and restated an IVD test development and component supply agreement with Illumina to extend the agreement term and increase the number of in vitro diagnostic test kits that may be developed using Illumina’s sequencing technology.

As the diagnostics industry launches high-throughput systems to large labs for HbA1c testing, clinicians also see a market need for point-of-care testing.

The firm's Q4 global influenza sales were up 60 percent year over year, and in 2016 its global infectious disease business achieved double-digit sales growth.

The firm also reported that both preliminary 2016 revenues and preliminary Q4 revenues would be down 3 percent. 

Roche's Bluetooth-enabled meter gives patients the option to bypass frequent trips to the clinic in favor of doing anticoagulation testing at home.   

Clinical trials show that people who use the system, which eliminates a painful finger stick, test glucose levels an average of 15 times each day.

The contract to Abbott is for the development of a traumatic brain injury assay. The estimated completion date of the contract is Oct. 23, 2019. 

First quarter results that blew away analysts' estimates lifted Exact Science's stock, while Abbott's new deal with Alere sparked that firm's share price. 

Arriva parent firm Alere said that it would proceed with an appeal of the revocation to HHS' Department Appeals Board.

Pages